INDIANAPOLIS — Patients with advanced lung cancer may be eligible for a new clinical study at the Indiana University Melvin and Bren Simon Cancer Center.
The study involves the oral drug LDK378. The study is comparing the effectiveness of LDK378 versus standard chemotherapy in adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer who have been treated previously with chemotherapy and crizotinib.
To qualify, participants must have a confirmed diagnosis of stage IIIB or IV non-small cell lung cancer and be 18 or older.
For additional information, contact Deb Estes, R.N., at 317-278-6599.